Marksans Pharma Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Mark Saldanha
Chief executive officer
₹68.9m
Total compensation
| CEO salary percentage | 69.7% |
| CEO tenure | 9.1yrs |
| CEO ownership | 43.8% |
| Management average tenure | 13yrs |
| Board average tenure | 6.3yrs |
Recent management updates
Recent updates
Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?
Oct 24
Optimistic Investors Push Marksans Pharma Limited (NSE:MARKSANS) Shares Up 45% But Growth Is Lacking
Sep 21Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 26% But Many Are Still Ignoring The Company
Jul 28Solid Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)
Jun 07Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?
May 31Sentiment Still Eluding Marksans Pharma Limited (NSE:MARKSANS)
Feb 16Here's Why Marksans Pharma (NSE:MARKSANS) Has Caught The Eye Of Investors
Jan 26We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease
Dec 02Marksans Pharma (NSE:MARKSANS) Seems To Use Debt Quite Sensibly
Jun 21Robust Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)
Nov 17This Is The Reason Why We Think Marksans Pharma Limited's (NSE:MARKSANS) CEO Deserves A Bump Up To Their Compensation
Sep 16Marksans Pharma (NSE:MARKSANS) Is Increasing Its Dividend To ₹0.25
Sep 01Marksans Pharma (NSE:MARKSANS) Could Easily Take On More Debt
Jun 14Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?
May 27Is Marksans Pharma (NSE:MARKSANS) A Risky Investment?
Feb 19Marksans Pharma Limited's (NSE:MARKSANS) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Feb 04Here's Why We Think Marksans Pharma (NSE:MARKSANS) Is Well Worth Watching
Jan 20Do Institutions Own Marksans Pharma Limited (NSE:MARKSANS) Shares?
Jan 05
Shareholders Are Thrilled That The Marksans Pharma (NSE:MARKSANS) Share Price Increased 250%
Dec 21What Can We Conclude About Marksans Pharma's (NSE:MARKSANS) CEO Pay?
Dec 06CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | ₹3b |
| Jun 30 2024 | n/a | n/a | ₹3b |
| Mar 31 2024 | ₹69m | ₹48m | ₹3b |
| Dec 31 2023 | n/a | n/a | ₹3b |
| Sep 30 2023 | n/a | n/a | ₹3b |
| Jun 30 2023 | n/a | n/a | ₹3b |
| Mar 31 2023 | ₹52m | ₹48m | ₹3b |
| Dec 31 2022 | n/a | n/a | ₹2b |
| Sep 30 2022 | n/a | n/a | ₹2b |
| Jun 30 2022 | n/a | n/a | ₹2b |
| Mar 31 2022 | ₹38m | ₹35m | ₹2b |
| Dec 31 2021 | n/a | n/a | ₹2b |
| Sep 30 2021 | n/a | n/a | ₹2b |
| Jun 30 2021 | n/a | n/a | ₹3b |
| Mar 31 2021 | ₹10m | ₹10m | ₹2b |
| Dec 31 2020 | n/a | n/a | ₹2b |
| Sep 30 2020 | n/a | n/a | ₹2b |
| Jun 30 2020 | n/a | n/a | ₹1b |
| Mar 31 2020 | ₹10m | ₹10m | ₹1b |
| Dec 31 2019 | n/a | n/a | ₹879m |
| Sep 30 2019 | n/a | n/a | ₹834m |
| Jun 30 2019 | n/a | n/a | ₹780m |
| Mar 31 2019 | ₹10m | ₹10m | ₹804m |
| Dec 31 2018 | n/a | n/a | ₹666m |
| Sep 30 2018 | n/a | n/a | ₹582m |
| Jun 30 2018 | n/a | n/a | ₹463m |
| Mar 31 2018 | ₹12m | ₹10m | ₹358m |
Compensation vs Market: Mark's total compensation ($USD814.92K) is above average for companies of similar size in the Indian market ($USD503.20K).
Compensation vs Earnings: Mark's compensation has increased by more than 20% in the past year.
CEO
Mark Saldanha (52 yo)
9.1yrs
Tenure
₹68,857,053
Compensation
Mr. Mark B. Saldanha, M.Sc. (Maths) & (Stat.)., Dip. (Fin. Mgt.) serves as Promoter and Managing Director of Marksans Pharma Limited, which he joined in October 6, 2005 (alternate name, Glenmark Laboratori...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Non-Independent Executive Chairman & MD | no data | ₹68.86m | 43.8% ₹ 61.4b | |
| Chief Financial Officer | 22.2yrs | ₹12.84m | no data | |
| Director Operations | no data | ₹5.80m | no data | |
| Company Secretary | 15.8yrs | ₹2.84m | no data | |
| Whole-Time Executive Non Independent Director | 10.2yrs | ₹7.07m | 0.073% ₹ 102.2m | |
| Whole-Time Executive Non Independent Director | 5.8yrs | ₹18.75m | no data | |
| Senior Vice President of QC | no data | ₹10.61m | no data | |
| Managing Director of Australia Operations | no data | no data | no data | |
| Managing Director of UK Operations | no data | no data | no data | |
| Chief Operating Officer of US Operations | no data | ₹10.29m | no data |
13.0yrs
Average Tenure
54yo
Average Age
Experienced Management: MARKSANS's management team is seasoned and experienced (13 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Non-Independent Executive Chairman & MD | 9.1yrs | ₹68.86m | 43.8% ₹ 61.4b | |
| Whole-Time Executive Non Independent Director | 10.2yrs | ₹7.07m | 0.073% ₹ 102.2m | |
| Whole-Time Executive Non Independent Director | 5.8yrs | ₹18.75m | no data | |
| Non-Executive & Non-Independent Director | 3.3yrs | no data | no data | |
| Non-Executive & Independent Director | 5.3yrs | ₹15.00k | no data | |
| Non-Executive & Independent Director | 1.5yrs | ₹300.00k | no data | |
| Non-Executive & Independent Director | 13.1yrs | ₹25.00k | no data | |
| Non-Executive Independent Director | 6.7yrs | ₹400.00k | no data |
6.3yrs
Average Tenure
53.5yo
Average Age
Experienced Board: MARKSANS's board of directors are considered experienced (6.3 years average tenure).